⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Fesoterodine

فزوترودین

⚠ Unverified

🚻 Genito Urinary System And Sex HormonesAntimuscarinic

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:No specific problem stated 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA022030 ATC G04BD11

Market / country: 🇺🇸 USA

Toviaz (US)

🧮 Dose calculator

Disease / regimen

Overactive bladder · Regimen source: FDA Toviaz · 2.1

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ Hypersensitivity to fesoterodine or tolterodine; urinary retention; gastric retention; uncontrolled narrow-angle glaucoma. FDA Toviaz · 4

Warnings

• Angioedema; urinary retention; decreased GI motility; CNS effects; worsening myasthenia gravis. FDA Toviaz · 5

Renal adjustment

• eGFR < 30: Adults CrCl 15–29: max 4 mg; lower per Table 1. FDA Toviaz · 2.3, Table 1

Formulations

4 mg ER tablet — tablet 🇺🇸 USA FDA Toviaz · 3
8 mg ER tablet — tablet 🇺🇸 USA FDA Toviaz · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Toviaz · 8.1
“Risk Summary There are no available data with the use of Toviaz in pregnant women and adolescents to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Toviaz · 8.2
“Risk Summary There is no information on the presence of fesoterodine in human milk, the effects on the breastfed child, or the effects on milk production.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Toviaz · 8.4
“The safety and effectiveness of Toviaz have been established for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 6 years and older and weighing greater than 25 kg.”
👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Toviaz · 8.5
“No dose adjustment is recommended for the elderly.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA022030
DailyMed (FDA label)FDA Toviaz
MedlinePlus (NIH)Fesoterodine
WHO ATC/DDDG04BD11
Darooyab (Iran)Fesoterodine

🇮🇷 Not found in Iran list Darooyab · G-4916/Fesoterodine

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Toviaz · 3 FDA Toviaz · 2.1 FDA Toviaz · 2 FDA Toviaz · 4 FDA Toviaz · 5 FDA Toviaz · 2.3, Table 1 FDA Toviaz · 8.1 FDA Toviaz · 8.2 FDA Toviaz · 8.4 FDA Toviaz · 8.5 FDA Toviaz · SPL approval / marketing category
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-4916/Fesoterodine
Clinical review⚠ Unverified

🔗 Similar drugs

For the same diseases

Darifenacin Mirabegron OnabotulinumtoxinA (Botox)Oxybutynin Solifenacin Tolterodine Trospium Vibegron